Answers go deeper than the script

Neurocrine Biosciences, Inc. (NBIX) — this company's answers

The model's full reasoning — Q4 2017 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. Gate 1: positive current development with Q&A adding more concrete operating detail than prepared remarks. Main positive is INGREZZA launch. Prepared remarks gave Q4 sales, scripts, transition to 80mg, free trial program, etc. Q&A: analysts ask about persistence, patient mix, payor mix, free trial impact, competitor, specialty pharmacy, physician feedback, 40mg dose proportion, formulary access. Management answers: mostly general, some specifics but not much new operational detail. For example persistence: "too early", no pattern. Patient mix: don't capture data, anecdotal. Payor mix: increasing Medicaid, shifted, no steady state. Free trial: "majority of treatment forms" requested, but no numbers. Competitor: not focused. Specialty pharmacy: added third due to growth. 40mg: within ballpark, too early. Formulary: prior auth, plans published coverage. These are somewhat additive but not substantial new specifics? Need decide. Also other developments: opicapone FDA meeting, CAH, Tourette. Q&A on opicapone: Eiry gives details on Phase I studies, potential Phase III design, timing. That is additive? Prepared remarks said met with FDA, need Phase I data initiated. Q&A adds specifics about hepatic impairment, patient PK, drug interaction, potential study design. But is that "positive current development" being probed? It's more regulatory/clinical plan, not current business going well. Gate 1 asks positive current development in company's business. INGREZZA launch is main. Q&A about INGREZZA: management answers with some new details but mostly qualitative. Need see if "produces more concrete operating detail than prepared remarks" across multiple exchanges. They mention "majority of treatment forms" free trial, "increasing Medicaid", "third specialty pharmacy due to growth", "prior auth requirements", "plans published coverage criteria". These are concrete but not quantified. Is that enough? The question says "substantive — actual operations, customers, volumes, timing, capacity, economics". Some are. But across multiple exchanges? Yes, several. However management often says "too early", "we don't capture", "not going to comment". Need weigh. Gate 2: Improvement filter. Main positive development is INGREZZA launch.

The model's full reasoning — Q2 2022 call → NOThe user wants me to evaluate the earnings call transcript against two gates. Let me analyze carefully. GATE 1 — ORIGINAL SIGNAL The question asks: Is there a POSITIVE, CURRENT development in the company's business for which the Q&A discussion PRODUCES MORE CONCRETE OPERATING DETAIL THAN THE PREPARED REMARKS CONTAINED? The main positive development here is INGREZZA's strong Q2 performance. Let me trace through the Q&A: 1. First question (Phil Nadeau) asks about what led to the increase in new patient starts in Q2. Matt responds about compliance rates, new patient additions, no onetime items. This is somewhat general. 2. Tazeen Ahmad asks about the INGREZZA results and whether compliance improved. Matt and Eric respond about compliance being looked at quarterly, new patient starts being a record. Eric adds that Q3 historically is slower. 3. Neena Bitritto-Garg asks about the impact of new sales reps on Q2. Eric responds about the sales force being recently deployed, taking time to hit stride, experienced hires but new to TD. 4. Jay Olson asks about 568 M4 agonist differentiation. 5. Carter Gould asks about DTC campaign contribution. Eric responds about the campaign meeting expectations, website visits, downloads, ROI assessment. 6. Anupam Rama asks about R&D expense increase - milestone payment. 7. Brian Skorney asks about sNDA for Huntington's. 8. Chris Shibutani asks about drug pricing legislation. 9. Myles Minter asks about 568 cardiovascular effects. 10. Danielle Brill asks about prescribing mix - Eric says it's similar to a quarter ago. 11. Laura Chico asks about peak run rate and exclusivity. 12. Charles Duncan's question about new prescribers vs. depth - Matt says mostly existing prescribers going deeper. 13. Evan Seigerman asks about inventory - Matt says stable. 14. Marc Goodman asks about gross to nets and ASP. 15. David Amsellem asks about long-term care contribution - Eric says it's very early. 16. Ami Fadia asks about neurology sales force - Eric says feedback positive, three quarters hired from outside. 17. Yatin Suneja asks about 352. Now, looking at the INGREZZA positive development - the Q2 performance.

The model's full reasoning — Q1 2024 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. Gate 1: positive current development with Q&A adding concrete operating detail beyond prepared remarks. Need identify. Main positive developments: INGREZZA growth, Crinecerfont NDA submission, NBI-845 positive Phase 2, sprinkle approval, pipeline. Q&A probes 845, muscarinic, Crinecerfont, INGREZZA. Does Q&A add concrete operating detail? For 845, management mostly deflects due IP, no specifics. For Crinecerfont, no new specifics. For INGREZZA, Q&A about average revenue per patient, long-term care. Management gives some detail on net revenue per script, seasonal gross-to-net, long-term care contribution. But is that "positive current development" with Q&A adding? The prepared remarks already had INGREZZA growth, long-term care progress. Q&A adds some specifics like long-term care contributing equal to neurology, net revenue per script ~5800. But is that substantial? Maybe. However, Gate 1 requires across multiple exchanges, additive. The Q&A mostly about 845 and muscarinic, but management doesn't add much. For INGREZZA, one exchange. For 845, no. For Crinecerfont, no. So Gate 1 likely NO. Gate 2: main positive current development? INGREZZA growth is company's own product, but Q&A not much. 845 is company's own. But Gate 1 fails. So answer NO. Need output exactly YES or NO.

← Back to the full NBIX analysis